Business Wire

Rawbank Conducts a USD 10 Million Commercial Paper to Support the Mining Industry and Strengthen the Congolese Economy

14.1.2025 11:52:00 CET | Business Wire | Press release

Share

Rawbank, the leading bank in the Democratic Republic of Congo, announces the launch of its second issue of commercial paper for a local mining operator in the Katanga region for the sum of USD 10 million. This transaction, arranged by Rawbank's trading room, confirms the bank's role as a key player in financial innovation in the DRC, while satisfying the strategic financing needs of companies operating in major sectors of the national economy.

Following the success of its first issuance in 2022, which marked a significant step forward for the financial market in the Democratic Republic of Congo, Rawbank has affirmed its pioneering role by introducing solutions that are ever-increasingly adapted to local conditions. A major innovation in this issuance is the inclusion of a corporate guarantee - a first in the DRC - which strengthens investor security and extends the financing options available on the money market. This transaction was approved by the Central Bank of the Congo (CBC) under Instruction 50, which regulates commercial paper.

Mustafa Rawji, Chief Executive Officer of Rawbank, declared: “This transaction strengthens our leadership position in the banking sector in the DRC and underscores our commitment to support the country's economic development. By facilitating access to financing for key businesses, we are contributing to the growth and diversification of the national economy.”

Etienne Mabunda, Commercial Director of Rawbank, stated: "This second issue of commercial paper bears witness to our ability to innovate and meet the specific needs of our institutional clients. Thanks to our trading room, which complies with international standards, we were able to structure this transaction in the best possible way, thus offering our investors better yields in a competitive market environment."

The mining industry, which accounts for more than 70% of the DRC's exports, remains a vital pillar of the Congolese economy. By giving a national operator access to competitive financing, this new issuance contributes directly to boosting economic activity in the region and strengthening investor confidence while, at the same time, stimulating local savings through attractive financial products.

About Rawbank

For 23 years, with total assets of USD 5 billion, Rawbank has supported the development of the Congolese economy. The leading bank in the DRC for 12 years, Rawbank provides the most modern products and services to over 500,000 corporate, SME, and individual clients through a network of more than 100 branches across 19 provinces, a digital offering with Illicocash, internet banking, and over 250 ATMs.

Its efforts have been recognized with the African Banker Awards for Best Regional Bank in Central Africa in 2022 and 2024, a Moody’s CAA 1 rating, and ISO/IEC 20000 and ISO/IEC 27001 certifications. Rawbank’s trusted partners include IFC, BAD, TDB, BADEA, Shelter Africa, AGF, among others.

Partners who have placed their trust in RAWBANK include: AfDB, AGF, IFC, BADEA, Shelter Africa, TDB and Afrexim. For more information, visit our website:www.rawbank.com

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250109301667/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye